Semaglutide has clinically beneficial effects on glucose metabolism and glycaemic status in patients with obesity and prediabetes. In this touchENDOCRINOLOGY interview, Dr Domenica Rubino (Washington Center for Weight Management and Research, Arlington, VA , USA) discusses her thoughts on the role of semaglutide in the treatment paradigm for prediabetes.
The abstract entitled: ‘Semaglutide 2.4 mg improved glucose metabolism and reverted prediabetes to normoglycaemia in adults with overweight or obesity vs liraglutide 3.0 mg (STEP 8) ‘ was presented at the European Association for the Study of Diabetes, 19-23 Sept, 2022.
Questions:
- What will be the role of semaglutide in the treatment paradigm for prediabetes? (0:14)
Disclosures: Domenica Rubino is a consultant for and discloses grant/research support from Boehringer Ingelheim and Novo Nordisk.
Support: Interview supported by Touch Medical Media. Interview conducted by Shanice Allen.
Recorded as a highlight of EASD 2022
